Quick Answer
Werewolf Therapeutics, Inc. reported Cash and Equivalents of $57.05 million for fiscal year 2025.
Werewolf Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $57.05M | -48.6% |
| 2024 | $111.00M | -17.4% |
| 2023 | $134.34M | +3.9% |
| 2022 | $129.31M | -17.9% |
| 2021 | $157.53M | +70.2% |
| 2020 | $92.57M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $65.71M | -46.5% | -15.3% |
| June 30, 2025 | $77.60M | -42.7% | -15.7% |
| March 31, 2025 | $92.04M | -33.9% | -17.1% |
| December 31, 2024 | $111.00M | -17.4% | -9.6% |
| September 30, 2024 | $122.83M | -5.6% | -9.2% |
| June 30, 2024 | $135.30M | -1.6% | -2.8% |
| March 31, 2024 | $139.19M | -5.9% | +3.6% |
| December 31, 2023 | $134.34M | +3.9% | +3.3% |
- Werewolf Therapeutics, Inc. showed a decrease of -48.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Werewolf Therapeutics, Inc.’s cash and equivalents has declined by 38.4% (from $92.57 million to $57.05 million).
- The most recent figure is from Werewolf Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: